keyword
MENU ▼
Read by QxMD icon Read
search

Tiotropium

keyword
https://www.readbyqxmd.com/read/28430820/cardiovascular-safety-of-tiotropium-respimat-vs-handihaler-in-the-routine-clinical-practice-a-population-based-cohort-study
#1
Francesco Trotta, Stefania Spila-Alegiani, Roberto Da Cas, Maja Rajevic, Valentino Conti, Mauro Venegoni, Mariangela Rossi, Giuseppe Traversa
The cardiovascular safety of tiotropium Respimat formulation in the routine clinical practice is still an open issue. Our aim was to compare the risk of acute myocardial infarction and heart rhythm disorders in incident users of either tiotropium Respimat or HandiHaler. The study population comprises patients aged ≥45 years, resident in two Italian regions with a first prescription of tiotropium (HandiHaler or Respimat) between 01/07/2011-30/11/2013. The cohort was identified through the database of prescriptions reimbursed by the Italian National Health Service...
2017: PloS One
https://www.readbyqxmd.com/read/28427541/long-term-safety-and-efficacy-of-glycopyrrolate-formoterol-metered-dose-inhaler-using-novel-co-suspension%C3%A2-delivery-technology-in-patients-with-chronic-obstructive-pulmonary-disease
#2
Nicola A Hanania, Donald P Tashkin, Edward M Kerwin, James F Donohue, Michael Denenberg, Denis E O'Donnell, Dean Quinn, Shahid Siddiqui, Chad Orevillo, Andrea Maes, Colin Reisner
BACKGROUND: The long-term safety and efficacy of a novel Co-Suspension™ Delivery Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 μg fixed-dose combination metered dose inhaler (GFF MDI) were investigated in a 28-week safety extension study (PINNACLE-3, NCT01970878) of two randomized controlled Phase III trials (PINNACLE-1 and -2; NCT01854645 and NCT01854658) in subjects with moderate-to-very severe chronic obstructive pulmonary disease (COPD). METHODS: Subjects completing 24 weeks' treatment with GFF MDI, GP MDI, FF MDI (all twice-daily) or open-label tiotropium 18 μg (once-daily) in PINNACLE-1 or -2 were randomly selected to continue treatment for 28 weeks...
May 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28424359/effects-of-combined-tiotropium-olodaterol-on-inspiratory-capacity-and-exercise-endurance-in-copd
#3
Denis E O'Donnell, Richard Casaburi, Peter Frith, Anne Kirsten, Dorothy De Sousa, Alan Hamilton, Wenqiong Xue, François Maltais
Two replicate, double-blind, 6-week, incomplete-crossover studies (MORACTO 1 and 2) assessed the effects of tiotropium/olodaterol on inspiratory capacity and exercise endurance time in patients with moderate to severe chronic obstructive pulmonary disease.For each patient, four of five treatments were administered once daily for 6 weeks, with a 21-day washout between treatments: tiotropium/olodaterol 2.5/5 µg or 5/5 µg, tiotropium 5 µg, olodaterol 5 µg or placebo, all via the Respimat inhaler...
April 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28406326/umeclidinium-for-the-treatment-of-uncontrolled-asthma
#4
Matteo Ferrando, Diego Bagnasco, Fulvio Braido, Ilaria Baiardini, Giovanni Passalacqua, Francesca Puggioni, Gilda Varricchi, Giorgio Walter Canonica
Smooth muscle cell contraction in the airways is the principal therapeutic target in asthmatic subjects and its insufficient treatment is often a cause of uncontrolled disease. For this reason, research has focused on targeting smooth muscle activity with anticholinergic agents, including umeclidinium. Areas Covered: This review highlights the potential application of umeclidinium, a long acting muscarinic antagonist, as a novel therapeutic approach for patients with severe uncontrolled asthma, despite maximal therapy...
April 13, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28399660/reply-to-can-a-better-patient-phenotyping-predict-the-efficacy-of-tiotropium-in-asthmatic-adolescents
#5
Eckard Hamelmann, Christian Vogelberg, Stanley J Szefler
No abstract text is available yet for this article.
April 11, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28399659/can-a-better-patient-phenotyping-predict-the-efficacy-of-tiotropium-in-asthmatic-adolescents
#6
Gennaro Liccardi, Luigino Calzetta, Antonello Salzillo, Amedeo Piccolo, Gloria Pane, Paola Rogliani
No abstract text is available yet for this article.
April 11, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28392684/cost-effectiveness-analysis-of-umeclidinium-vilanterol-for-the-management-of-patients-with-moderate-to-very-severe-copd-using-an-economic-model
#7
Michele R Wilson, Jeetvan G Patel, Amber Coleman, Cheryl L McDade, Richard H Stanford, Stephanie R Earnshaw
BACKGROUND: Bronchodilators such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) are central to the pharmacological management of COPD. Dual bronchodilation with umeclidinium/vilanterol (UMEC/VI; 62.5/25 μg) is a novel LAMA/LABA combination approved for maintenance treatment for patients with COPD. OBJECTIVE: The objective of this study was to assess the cost-effectiveness of maintenance treatment with UMEC/VI compared with tiotropium (TIO) 18 μg, open dual LAMA + LABA treatment, or no long-acting bronchodilator treatment in patients with moderate to very severe COPD...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28385353/single-inhaler-extrafine-triple-therapy-versus-long-acting-muscarinic-antagonist-therapy-for-chronic-obstructive-pulmonary-disease-trinity-a-double-blind-parallel-group-randomised-controlled-trial
#8
Jørgen Vestbo, Alberto Papi, Massimo Corradi, Viktor Blazhko, Isabella Montagna, Catherine Francisco, Géraldine Cohuet, Stefano Vezzoli, Mario Scuri, Dave Singh
BACKGROUND: Limited data are available for the efficacy of triple therapy with two long-acting bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease (COPD). We compared treatment with extrafine beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB; fixed triple) with tiotropium, and BDP/FF plus tiotropium (open triple). METHODS: For this double-blind, parallel-group, randomised, controlled trial, eligible patients had COPD, post-bronchodilator forced expiratory volume in 1 s (FEV1) of less than 50%, at least one moderate-to-severe COPD exacerbation in the previous 12 months, and a COPD Assessment Test total score of at least 10...
April 3, 2017: Lancet
https://www.readbyqxmd.com/read/28383865/-spiolto-respimat%C3%A2-tiotropium-olodaterol-fixed-combination-for-therapy-of-chronic-obstructive-pulmonary-disease-copd
#9
REVIEW
D Cataldo
Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway disease that can be prevented and treated. The recommendations for therapy include bronchodilators from two classes (LAMA (Long Acting Muscarinic Antagonists) and LABA (Long Acting Beta2 Agonists)). Spiolto Respimat® is a LAMA/LABA combination therapy and comprises tiotropium (Spiriva®) and olodaterol (a LABA). Clinical studies show that Spiolto Respimat® is able to improve lung function tests (Increased FEV1, decreased hyperinflation and residual volume) and quality of life as compared to tiotropium or olodaterol...
June 2016: Revue Médicale de Liège
https://www.readbyqxmd.com/read/28344980/discordance-in-investigator-reported-and-adjudicated-sudden-death-in-tiospir
#10
Robert A Wise, Peter R Kowey, George Austen, Achim Mueller, Norbert Metzdorf, Andy Fowler, Lorcan P McGarvey
Accurate and consistent determination of cause of death is challenging in chronic obstructive pulmonary disease (COPD) patients. TIOSPIR (N=17 135) compared the safety and efficacy of tiotropium Respimat 5/2.5 µg with HandiHaler 18 µg in COPD patients. All-cause mortality was a primary end-point. A mortality adjudication committee (MAC) assessed all deaths. We aimed to investigate causes of discordance in investigator-reported and MAC-adjudicated causes of death and their impact on results, especially cardiac and sudden death...
January 2017: ERJ Open Research
https://www.readbyqxmd.com/read/28292484/external-validation-of-health-economic-decision-models-for-chronic-obstructive-pulmonary-disease-copd-report-of-the-third-copd-modeling-meeting
#11
Martine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, Andrew H Briggs, Ryan N Hansen, Reiner Leidl, Nancy Risebrough, Yevgeniy Samyshkin, Margarethe Wacker, Maureen P M H Rutten-van Mölken
OBJECTIVES: To validate outcomes of presently available chronic obstructive pulmonary disease (COPD) cost-effectiveness models against results of two large COPD trials-the 3-year TOwards a Revolution in COPD Health (TORCH) trial and the 4-year Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) trial. METHODS: Participating COPD modeling groups simulated the outcomes for the placebo-treated groups of the TORCH and UPLIFT trials using baseline characteristics of the trial populations as input...
March 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28280319/umeclidinium-vilanterol-as-step-up-therapy-from-tiotropium-in-patients-with-moderate-copd-a-randomized-parallel-group-12-week-study
#12
Edward M Kerwin, Chris J Kalberg, Dmitry V Galkin, Chang-Qing Zhu, Alison Church, John H Riley, William A Fahy
INTRODUCTION: Patients with COPD who remain symptomatic on long-acting bronchodilator monotherapy may benefit from step-up therapy to a long-acting bronchodilator combination. This study evaluated the efficacy and safety of umeclidinium (UMEC)/vilanterol (VI) in patients with moderate COPD who remained symptomatic on tiotropium (TIO). METHODS: In this randomized, blinded, double-dummy, parallel-group study (NCT01899742), patients (N=494) who were prescribed TIO for ≥3 months at screening (forced expiratory volume in 1 s [FEV1]: 50%-70% of predicted; modified Medical Research Council [mMRC] score ≥1) and completed a 4-week run-in with TIO were randomized to UMEC/VI 62...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28279286/a-63-year-old-woman-with-progressive-dyspnea-after-remission-of-lymphoma
#13
Tomoe Nishihara, Hiroshi Nakano, Hiroko Nogami, Katsuyuki Katahira, Akiko Ishimatsu, Naozumi Hashimoto, Toyoharu Yokoi, Tomoaki Iwanaga
A 63-year-old woman visited our hospital for a further evaluation of progressive dyspnea. She had developed a progressive airflow obstruction after 3 years' remission of non-Hodgkin's lymphoma (follicular mixed cell type), which had been treated with chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). The patient's primary care physician had diagnosed her as having COPD and bronchial asthma and had treated her with medications including inhaled corticosteroids, tiotropium, and oral erythromycin...
March 2017: Chest
https://www.readbyqxmd.com/read/28276136/initial-diagnosis-and-management-of-chronic-obstructive-pulmonary-disease-in-australia-views-from-the-coal-face
#14
Bonnie Bereznicki, Haydn Walters, Julia Walters, Gregory Peterson, Luke Bereznicki
BACKGROUND: Early diagnosis and management can mitigate the long-term morbidity and mortality of chronic obstructive pulmonary disease (COPD). AIM: To gain insights into the initial diagnostic process and early management of COPD by Australian general practitioners (GPs). METHODS: A random sample of Australian GPs was invited to complete a postal survey, which assessed familiarity with and use of contemporary practice guidelines, diagnostic criteria, and management preferences for COPD...
March 9, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28274527/long-term-safety-and-efficacy-of-combined-tiotropium-and-olodaterol-in-japanese-patients-with-chronic-obstructive-pulmonary-disease
#15
Masakazu Ichinose, Motokazu Kato, Ayako Takizawa, Wataru Sakamoto, Lars Grönke, Kay Tetzlaff, Yoshinosuke Fukuchi
BACKGROUND: The efficacy and safety of once-daily tiotropium+olodaterol (T+O) (2.5/5µg or 5/5µg) for treating chronic obstructive pulmonary disease (COPD) have been demonstrated in the large, multinational, randomized, Phase III studies TONADO(®) 1 and 2, which included 413 Japanese patients (~80 in each group). This study was conducted to supplement the TONADO(®) study data to assess long-term safety in ≥100 Japanese patients treated for 1 year in compliance with International Conference on Harmonisation guidelines...
March 2017: Respiratory Investigation
https://www.readbyqxmd.com/read/28228162/efficacy-and-safety-of-indacaterol-glycopyrronium-fixed-dose-combination-in-mild-to-moderate-copd-patients-symptomatic-on-tiotropium-in-korea-study-protocol-for-a-randomized-controlled-trial
#16
Chin Kook Rhee, Hye Yun Park, Jeong-Woong Park, Ji-Hyun Lee, Tae-Hyung Kim, Sei Won Lee, Ji Ye Jung, Song Kim, Yong Il Hwang, Ki-Suck Jung
BACKGROUND: Long-acting bronchodilator monotherapy (long-acting β2-agonist [LABA] or long-acting muscarinic antagonist [LAMA]) is extensively used for treatment of patients with chronic obstructive pulmonary disease (COPD) with mild-to-moderate airflow limitation. However, a substantial number of patients remain symptomatic despite treatment with a single bronchodilator, necessitating a change in therapy. METHODS: This 12-week, randomized, multicenter, open-label, phase IV study aims to show that the once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μg fixed-dose LABA/LAMA combination results in an improved lung function in symptomatic patients with mild-to-moderate COPD who switch from once-daily tiotropium 18 μg...
February 22, 2017: Trials
https://www.readbyqxmd.com/read/28212954/evaluation-of-copd-treatments-a-multicriteria-decision-analysis-of-aclidinium-and-tiotropium-in-the-united-states
#17
Kevin Marsh, Erica Zaiser, Panagiotis Orfanos, Suzanne Salverda, Teresa Wilcox, Shawn Sun, Shailja Dixit
BACKGROUND: Comparisons of the use of aclidinium bromide and tiotropium bromide for the treatment of chronic obstructive pulmonary disease often concentrate on key end points (exacerbations) at the expense of other benefits and risks. Multicriteria decision analysis (MCDA) can help overcome this by using stakeholder preferences to combine multiple end points into an overall value estimate. OBJECTIVES: To evaluate the use of aclidinium bromide twice daily via Pressair™ (AstraZeneca Pharmaceuticals LP, Wilmington, DE) and of tiotropium once daily via HandiHaler(®) (Boehringer Ingelheim Pharmaceuticals, Inc...
January 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28203364/tiotropium-formulations-and-safety-a-network-meta-analysis
#18
Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera
Tiotropium is now delivered via two different inhaler devices: the original Handihaler 18 μg once daily, which uses a powder formulation; and the newer Respimat Soft Mist Inhaler (SMI) 5 μg once daily. It has been questioned whether the two devices can be assumed to have the same safety profile, although the TIOSPIR trial showed that tiotropium when administered via Respimat SMI 5 μg is not less safe than Handihaler 18 μg. Therefore, we have carried out a safety evaluation of tiotropium Handihaler 18 µg versus tiotropium Respimat SMI 5 µg and 2...
January 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/28154373/effect-of-tiotropium-and-olodaterol-on-symptoms-and-patient-reported-outcomes-in-patients-with-copd-results-from-four-randomised-double-blind-studies
#19
Gary T Ferguson, Jill Karpel, Nathan Bennett, Emmanuelle Clerisme-Beaty, Lars Grönke, Florian Voß, Roland Buhl
Chronic obstructive pulmonary disease is associated with significant morbidity and mortality. Trials of maintenance chronic obstructive pulmonary disease treatments focus on improvement in lung function and reductions in exacerbations, while patients are much more concerned about symptoms and health status. Our aim was to investigate the effects of tiotropium + olodaterol on patient-reported health outcomes, breathlessness and night-time rescue medication use in patients with chronic obstructive pulmonary disease, compared to placebo, tiotropium or olodaterol monotherapy...
December 2017: NPJ Primary Care Respiratory Medicine
https://www.readbyqxmd.com/read/28140686/role-of-muscarinic-antagonists-in-asthma-therapy
#20
Mario Cazzola, Josuel Ora, Paola Rogliani, Maria Gabriella Matera
Higher parasympathetic tone has been reported in asthmatics. In general, cholinergic contractile tone is increased by airway inflammation associated with asthma. Nevertheless, the role of muscarinic antagonists for the treatment of asthma has not yet been clearly defined. Areas covered: The use of SAMAs and LAMAs in asthma has been examined and discussed according with the published evidence. Particular attention has been given to the large Phase III clinical trial program designed to evaluate the efficacy and safety of tiotropium respimat added to standard treatment in adults, adolescents and children with persistent asthma across the spectrum of asthma severity...
March 2017: Expert Review of Respiratory Medicine
keyword
keyword
8894
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"